John Paul II Hospital, Kraków, Poland.
Jagiellonian University Medical College, Kraków, Poland.
Diabetologia. 2021 Nov;64(11):2562-2574. doi: 10.1007/s00125-021-05545-w. Epub 2021 Sep 7.
AIMS/HYPOTHESIS: Type 2 diabetes has been demonstrated to predispose to aortic valve calcification. We investigated whether type 2 diabetes concomitant to aortic stenosis (AS) enhances valvular inflammation and coagulation activation via upregulated expression of NF-κB, with subsequent increased expression of bone morphogenetic protein 2 (BMP-2). METHODS: In this case-control study, 50 individuals with severe isolated AS and concomitant type 2 diabetes were compared with a control group of 100 individuals without diabetes. The median (IQR) duration of diabetes since diagnosis was 11 (7-18) years, and 36 (72%) individuals had HbA ≥48 mmol/mol (≥6.5%). Stenotic aortic valves obtained during valve replacement surgery served for in loco NF-κB, BMP-2, prothrombin (FII) and active factor X (FXa) immunostaining. In vitro cultures of valve interstitial cells (VICs), isolated from obtained valves were used for mechanistic experiments and PCR investigations. RESULTS: Diabetic compared with non-diabetic individuals displayed enhanced valvular expression of NF-κB, BMP-2, FII and FXa (all p ≤ 0.001). Moreover, the expression of NF-κB and BMP-2 positively correlated with amounts of valvular FII and FXa. Only in diabetic participants, valvular NF-κB expression was strongly associated with serum levels of HbA, and moderately with fructosamine. Of importance, in diabetic participants, valvular expression of NF-κB correlated with aortic valve area (AVA) and maximal transvalvular pressure gradient. In vitro experiments conducted using VIC cultures revealed that glucose (11 mmol/l) upregulated expression of both NF-κB and BMP-2 (p < 0.001). In VIC cultures treated with glucose in combination with reactive oxygen species (ROS) inhibitor (N-acetyl-L-cysteine), the expression of NF-κB and BMP-2 was significantly suppressed. A comparable effect was observed for VICs cultured with glucose in combination with NF-κB inhibitor (BAY 11-7082), suggesting that high doses of glucose activate oxidative stress leading to proinflammatory actions in VICs. Analysis of mRNA expression in VICs confirmed these findings; glucose caused a 6.9-fold increase in expression of RELA (NF-κB p65 subunit), with the ROS and NF-κB inhibitor reducing the raised expression of RELA by 1.8- and 3.2-fold, respectively. CONCLUSIONS/INTERPRETATION: Type 2 diabetes enhances in loco inflammation and coagulation activation within stenotic valve leaflets. Increased valvular expression of NF-κB in diabetic individuals is associated not only with serum HbA and fructosamine levels but also with AVA and transvalvular gradient, indicating that strict long-term glycaemic control is needed in AS patients with concomitant type 2 diabetes. This study suggests that maintaining these variables within the normal range may slow the rate of AS progression.
目的/假设:2 型糖尿病已被证明易导致主动脉瓣钙化。我们研究了 2 型糖尿病是否会通过 NF-κB 的上调表达,继而增加骨形态发生蛋白 2(BMP-2)的表达,从而增强主动脉瓣狭窄(AS)合并 2 型糖尿病患者的瓣叶炎症和凝血激活。
方法:在这项病例对照研究中,我们比较了 50 名患有严重孤立性 AS 且合并 2 型糖尿病的患者与 100 名无糖尿病的对照组患者。自确诊以来,糖尿病的中位数(IQR)持续时间为 11(7-18)年,36(72%)名患者的 HbA 大于 48mmol/mol(大于 6.5%)。在瓣膜置换术中获得的狭窄主动脉瓣用于原位 NF-κB、BMP-2、凝血酶原(FII)和活性因子 X(FXa)免疫染色。从获得的瓣膜中分离出的瓣膜间质细胞(VIC)用于进行机制实验和 PCR 研究。
结果:与非糖尿病患者相比,糖尿病患者的瓣 NF-κB、BMP-2、FII 和 FXa 表达增强(均 P 值小于 0.001)。此外,NF-κB 和 BMP-2 的表达与瓣 FII 和 FXa 的含量呈正相关。只有在糖尿病患者中,瓣 NF-κB 表达与血清 HbA 水平呈强相关,与果糖胺呈中度相关。重要的是,在糖尿病患者中,瓣 NF-κB 表达与主动脉瓣面积(AVA)和最大跨瓣压力梯度相关。使用 VIC 培养物进行的体外实验表明,葡萄糖(11mmol/l)上调 NF-κB 和 BMP-2 的表达(P 值均小于 0.001)。在葡萄糖联合活性氧(ROS)抑制剂(N-乙酰-L-半胱氨酸)处理的 VIC 培养物中,NF-κB 和 BMP-2 的表达明显受到抑制。用葡萄糖联合 NF-κB 抑制剂(BAY 11-7082)培养的 VIC 也观察到类似的效果,表明高剂量的葡萄糖激活氧化应激,导致 VIC 产生促炎作用。VIC 中 mRNA 表达的分析证实了这些发现;葡萄糖使 RELA(NF-κB p65 亚基)的表达增加了 6.9 倍,而 ROS 和 NF-κB 抑制剂使 RELA 的表达分别降低了 1.8 倍和 3.2 倍。
结论/解释:2 型糖尿病增强了狭窄瓣叶内的局部炎症和凝血激活。糖尿病患者瓣 NF-κB 的表达增加不仅与血清 HbA 和果糖胺水平相关,还与 AVA 和跨瓣梯度相关,这表明伴有 2 型糖尿病的 AS 患者需要严格的长期血糖控制。这项研究表明,将这些变量维持在正常范围内可能会减缓 AS 进展的速度。
J Heart Valve Dis. 2014-9
J Am Heart Assoc. 2016-11-4
Arterioscler Thromb Vasc Biol. 2012-9-13
Am J Physiol Heart Circ Physiol. 2020-9-28
Front Endocrinol (Lausanne). 2025-7-30
Front Immunol. 2025-2-26
J Am Heart Assoc. 2020-7-7
Diab Vasc Dis Res. 2019-1-9
Int J Cardiol. 2018-3-24
Circ Cardiovasc Imaging. 2018-3